iiinova — where your digital self keeps evolving

RIO Trial

@riotrial.bsky.social

Hello, RIO Trial is also now on Bluesky! The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time. riotrial.org

Posts Replies Media

RIO Trial @riotrial.bsky.social · 23/04/2025

@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs

063

RIO Trial @riotrial.bsky.social · 10/04/2025

People who receive bNAbs respond differently, some experience delayed rebound beyond 20 weeks after one dose, and some do not rebound at all. However some people still experienced early rebound despite being screened for predicted bNAb resistance. #KeystoneSymposium #HIVcure2025

Chart showing 3 patterns of viral rebound in people in the RIO study

000

RIO Trial @riotrial.bsky.social · 10/04/2025

Dr Ming Lee, RIO trial physician @drmjlee.bsky.social presents the primary findings from RIO and his gut sub-study at the Keystone HIV cure conference in Durban, S. Africa. #KeystoneSymposium #HIVcure

Ming Lee presenting his conference talk titled 'The use of long-acting broadly neutralising antibodies to confer HIV viral control'

020

RIO Trial @riotrial.bsky.social · 13/03/2025

RIO is an international collaboration bringing together researchers from Rockefeller, Imperial College London, University of Oxford, and clinical sites across UK and Europe. Here are some of our investigators unwinding after the #CROI2025 conference in San Francisco.

091

RIO Trial @riotrial.bsky.social · 11/03/2025

This study is the first to show sustained viral control using these immune-based therapies. The bNAbs not only targeted HIV directly but also stimulated the immune system, with some participants achieving undetectable levels of HIV in their reservoirs.

100

RIO Trial @riotrial.bsky.social · 11/03/2025

The results showed that 75% of participants who received bNAbs were able to control the virus for 20 weeks, compared to those who received a placebo over the same timeframe.

100

RIO Trial @riotrial.bsky.social · 11/03/2025

Yesterday at the #CROI2025 conference in San Francesco, we were delighted to report promising results of the primary outcome of our RIO Trial , which tested long-acting immune-based therapies for HIV.

120

RIO Trial @riotrial.bsky.social · 11/03/2025

RIO Chief Investigator, Prof Sarah Fidler, presented the RIO primary results at CROI Conference 10 Mar 2025. Three quarters of participants who received bNAbs were able to control the virus while off their antiretroviral therapy, compared to those who received a placebo over a 20-week period.

Prof Sarah Fidler, RIO Chief Investigator, presenting the primary outcome results at the CROI Conference yesterday, 10 Mar 2025.

094